VF
TELO icon

Virtu Financial’s Telomir Pharmaceuticals TELO Stock Holding History

Virtu Financial’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,278
Closed -$19K – 2407
2025
Q4 		$19K Buy
+14,278
New +$20.6K ﹤0.01% 1439
2025
Q1 		– Sell
-14,959
Closed -$62K – 2143
2024
Q4 		$62K Buy
+14,959
New +$70.5K ﹤0.01% 1121

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Virtu Financial's TELO Position: Q1 2026 in Review

Virtu Financial sold out of Telomir Pharmaceuticals (TELO) in Q1 2026, closing a stake of 14,278 shares — an estimated $19K sold.

Virtu Financial first reported a position in TELO in Q4 2024 and held it in 2 quarters. The position peaked at $62K in Q4 2024. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • Virtu Financial reported no remaining Telomir Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 14,278 Telomir Pharmaceuticals shares in Q1 2026, an estimated $19K.
  • Virtu Financial first reported a position in Telomir Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Virtu Financial's Telomir Pharmaceuticals position peaked at $62K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.